Editas Medicine (EDIT) Fundamental Analysis: Revenue, Earnings & Valuation

3.26 / 10

Netural

Fundamental analysis rates the stock neutral with a 3.3/10 score. Positive points include PB‑ROE and cash‑to‑market value, while asset‑to‑market and fixed‑asset turnover lag. Revenue growth is high (25% YoY) but margins and tax ratios offer limited upside, indicating overall weakness.

Analysis Checks(5/10)

Revenue-MV

Value-0.26

Score1/3

Weight13.38%

1M Return4.95%

Total operating revenue (YoY growth rate %)

Value25.39

Score1/3

Weight-6.34%

1M Return-3.06%

Inventory turnover ratio

Value103.94

Score3/3

Weight17.75%

1M Return6.74%

Gross profit margin (%)

Value100.00

Score2/3

Weight4.05%

1M Return1.69%

PB-ROE

Value-0.16

Score2/3

Weight16.79%

1M Return6.97%

Income tax / Total profit (%)

Value21.05

Score1/3

Weight-1.02%

1M Return-0.50%

Fixed assets turnover ratio

Value1.21

Score1/3

Weight-2.48%

1M Return-1.24%

Cost of sales ratio (%)

Value64.41

Score3/3

Weight10.27%

1M Return4.32%

Asset-MV

Value-0.55

Score1/3

Weight31.83%

1M Return11.07%

Cash-MV

Value0.02

Score2/3

Weight15.77%

1M Return5.94%

Is EDIT undervalued or overvalued?

EDIT scores 3.26/10 on fundamentals and holds a Fair valuation at present. Backed by its -198.14% ROE, -395.01% net margin, -1.51 P/E ratio, 8.86 P/B ratio, and 37.50% earnings growth, these metrics solidify its Netural investment rating.